INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. \[[@R1]\] It is well recognized that hepatic resection is the primary radical treatment for HCC. \[[@R2]\]

Recently, many new instruments, such as the TissueLink and Cavitron Ultrasonic Surgical Aspirator, have been developed to improve hepatic resections. \[[@R3]\] However, these techniques often require intraoperative maneuvers, including hepatic pedicle clamping, hypotensive anesthetics, which increased ischemic injury and risk of air embolism. \[[@R4]\]

The Habib^TM^ 4X, a newer bipolar radiofrequency ablation introduced in 2007, creates a plane of coagulative necrosis along the intended line of parenchymal transection. \[[@R5], [@R6]\] The Habib^TM^ 4X is a promising device for decreasing blood loss \[[@R7]\], without performing a Pringle maneuver. \[[@R8]\] To date, the safety and outcomes of patients who have undergone hepatic resection with the Habib^TM^ 4X have been controversial. \[[@R9], [@R10]\]

To further address this issue, we conducted this retrospective study to compare the Habib^TM^ 4X with clamp-crush in terms of complications, recurrence-free survival (RFS), and overall survival (OS) of patients. Furthermore, as a retrospective study, we used a propensity-scoring matched (PSM) model to balance the effects of variables before resection.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

A total of 183 HCC patients who underwent hepatic resections were enrolled. Eighty-one (44.3%) patients were underwent resections with the Habib^TM^ 4X (Habib group), and 102 (55.7%) patients underwent clamp-crush resection (CC group). Overall, there were 159 (86.9%) male and 23 (13.1%) female patients. The median age was 51.0 years (range: 22-79 years). During a median follow-up of 41.5 months (range: 4.0-79.5 months), 91 patients (49.7%) experienced recurrence, and 62 patients (33.9%) died. The 2- and 5-year OS rates were 76.9% and 52.3%, and the 2- and 5-year RFS rates were 55.4% and 43.7%, respectively.

Outcomes before matching {#s2_2}
------------------------

Table [1](#T1){ref-type="table"} summarizes preoperative and operative patient characteristics. Among the Habib group, 2 patients suffered bile leakage, 1 patient suffered hemorrhage, and 1 patient suffered liver failure. These were all major complications (Clavien-Dindo grade III-IV). Among the CC group, 3 patients developed bile leakage, 3 patients suffered hemorrhage, 2 patients suffered liver failure, and 1 patient suffered a severe lung infection, which were assigned as Clavien-Dindo grade III-IV (major complications). Neither group had dead within 30 days after resection. No significant differences in postoperative complications were observed between the two groups (*P* = 0.310).

###### Clinicopathological factors of patients before and after propensity matched

                                        Before propensity matching   After propensity matching                                       
  ------------------------------------- ---------------------------- --------------------------- --------- ------------ ------------ ---------
  Ages (years)                          54.0±12.7                    50±11.7                     0.300     53.0±12.5    51.0±12.1    0.752
  Gender (male: female)                 69:12                        90:12                       0.544     58:9         58:9         1.000
  HBsAg (positive : negative)           65:15                        89:13                       0.265     56:11        59:8         0.458
  AFP (≤25: \>25ng/ml)                  34:47                        34:68                       0.229     27:40        22:45        0.370
  White blood cell (X10\^9/L)           6.1±2.2                      6.5±2.1                     0.732     5.9±2.2      6.2±2.2      0.699
  Platelet count (X10\^9/L)             167±91.1                     151.5±87.7                  0.453     166.0±71.7   145.0±99.5   0.930
  ALT (U/L)                             42.0±54.8                    41.0±39.2                   0.099     41.0±68.3    41.0±31.5    0.269
  AST (U/L)                             45.0±31.3                    43.5±20.6                   0.259     42.0±31.4    45.0±20.4    0.404
  GGT (U/L)                             54.0±22.9                    50.0±17.1                   0.044     51.0±51.7    53.0±27.4    0.355
  Albumin (g/L)                         38.5±7.5                     41.0±4.2                    0.001     38.8±7.7     40.6±4.5     0.007
  Total bilirubin (umol/L)              18.6±14.7                    16.0±6.9                    0.063     16.5±14.8    16.0±6.8     0.229
  Prothrombin time (s)                  14.0±1.8                     13.6±1.5                    0.885     14.0±1.8     13.5±1.3     0.805
  Ascites (absence : presence)          74:7                         89:13                       0.377     65:2         66:1         1.000
  Tumor number (solitary : multiple)    60:21                        71:31                       0.506     49:18        50:17        0.844
  Tumor size (cm)                       6.5±2.7                      5.5±4.0                     0.007     5.5±2.4      5.0±3.1      0.463
  Location (central : peripheral) ^a^   45:36                        52:51                       0.494     39:28        37:30        0.290
  PVTT (absence : presence)             72:9                         84:18                       0.216     63:4         63:4         1.000
  Pathological stage (I-II:III-IV)      39:42                        51:51                       0.803     32:35        39:28        0.226
  Blood loss (ml)                       150±572                      250±674                     0.005     175±533      250±467      0.037
  Blood transfusion (no : yes)          71:10                        77:25                       0.038     60:7         49:18        0.015
  Pringle maneuver (no : yes)           72:9                         59:53                       \<0.001   63:4         38:29        \<0.001
  Surgical margin (\<2 : ≥2 cm)         24:58                        47:65                       0.143     20:47        32:35        0.033
  Operative time (minutes)              160±61                       196±54                      0.001     167±51       190±30       0.001
  Complication grade (0-II: III-IV)     77:4                         93:9                        0.310     65:2         62:5         0.437
  Hospital stays after surgery (days)   10.0±2.8                     11.0±3.6                    0.106     10.0±2.8     10.0±2.3     0.327

^a^ Central location is defined as tumor with a distance of ≥2cm from the liver capsule. The rest lesions are defined as peripheral.

Abrreviations: CC, clamp-crush, HBsAg, hepatitis B virus surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombi.

Compared with the CC group, the Habib group had higher levels of γ-glutamyltransferase (GGT; *P* = 0.044) and albumin (*P* = 0.001), larger tumors (*P* = 0.007), shorter operation times (*P* = 0.001), less intraoperative blood loss (*P* = 0.005), fewer intraoperative blood transfusions (*P* = 0.038), and fewer Pringle maneuvers (*P* = 0.001). The 2- and 5-year RFS rates were 61.2% and 52.8%, respectively, for the Habib group, and 50.1% and 40.2%, respectively, for the CC group (*P* = 0.112, Figure [1A](#F1){ref-type="fig"}). The 2- and 5-year OS rates were 80.5% and 56.2%, respectively, for the Habib group, and 73.2% and 45.5%, respectively, for the CC group (*P* = 0.112, Figure [1B](#F1){ref-type="fig"}).

![Kaplan-Meier analyses of recurrence-free survival **A**. and overall survival **B**. of patients with HCC before matching.](oncotarget-08-4218-g001){#F1}

Outcomes after matching {#s2_3}
-----------------------

As mentioned before, the two groups have different baseline levels of several important preoperative clinical factors, including GGT and albumin levels as well as tumor size. Thus, we used the PSM method to balance bias. Using PSM, 67 paired patients were selected. The variable balance in the matched cohort was markedly improved, and no significant difference was observed between the two groups with respect to preoperative demographics (Table [1](#T1){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). For the Habib group, 1 patient suffered bile leakage, and 1 patient suffered hemorrhage. For the CC group, 2 patients suffered bile leakage, 2 patients suffered hemorrhage, and 1 patient suffered liver failure. No significant difference in complications was observed between the two groups (*P* = 0.437).

![Parallel line plots of the standardized differences in means before and after PSM in patients with HCC **A**. Dot plots of the propensity scores of patients in the Habib and CC groups, showing individuals in the dataset and whether they were matched or discarded.](oncotarget-08-4218-g002){#F2}

Compared with the CC group, the Habib group had shorter operation times (*P* = 0.001), less blood loss (*P* = 0.037), blood transfusions (*P* = 0.015), and Pringle maneuvers (*P* = 0.001). During a median follow-up of 42.5 months (range: 4.0-74.0 months), 60 patients (44.8%) developed recurrence, and 41 patients (30.6%) died.

The associations of clinicopathological factors with RFS and OS are presented in Table [2](#T2){ref-type="table"}. The 2- and 5-year RFS rates were 73.2% and 60.6%, respectively, in the Habib group, and 51.2% and 40.2%, respectively, in the CC group (*P* = 0.033, Figure [3A](#F3){ref-type="fig"}). The 2- and 5-year OS rates were 86.5% and 62.9%, respectively, in the Habib group, and 80.5% and 40.2%, respectively, in the CC group (*P* = 0.014, Figure [3B](#F3){ref-type="fig"}).

###### Clinicopathological factor associated with the survival in matching patients

  Variables                  Recurrence-free survival rate (%)   Overall survival rate (%)                                         
  -------------------------- ----------------------------------- --------------------------- --------- ------------- ------------- ---------
  Gender                                                                                                                           
  Male: Female               49.7 : 60.2                         49.7 : 52.1                 0.605     78.4 : 79.6   55.0 : 55.6   0.776
  Age (years) ^a^                                                                                                                  
  ≤ 54 : \>54                60.6 : 53.5                         53.5 : 48.4                 0.642     81.2 : 82.0   59.2 : 45.1   0.525
  HBsAg                                                                                                                            
  Negative : Positive        61.7: 61.7                          58.4 : 50.1                 0.563     82.3 : 81.3   61.5 : 54.5   0.635
  AFP level (ng/ml)                                                                                                                
  ≤ 25: \> 25                59.1 : 57.7                         53.3 : 49.9                 0.953     78.4 : 80.6   50.8 : 59.6   0.895
  ALT (U/L)                                                                                                                        
  ≤40 : \>40                 59.2 : 58.5                         52.6 : 50.6                 0.526     85.0 : 78.3   56.1 : 55.6   0.446
  AST (U/L)                                                                                                                        
  ≤40 : \>40                 60.6 : 57.5                         56.7 : 48.8                 0.373     84.6 : 79.2   57.8 : 54.8   0.367
  GGT (U/L)                                                                                                                        
  ≤50 : \>50                 71.5 : 55.9                         65.0 : 48.2                 0157      91.6 : 79.0   78.6 : 49.4   0.039
  Albumin                                                                                                                          
  ≤ 35: \> 35                58.3 : 58.8                         43.2 : 52.9                 0.124     70.0 : 80.5   36.9: 59.5    0.080
  Total bilirubin (umol/L)                                                                                                         
  ≤17.1 : \>17.1             58.3 : 65.8                         53.2: 0                     0.135     81.0 : 88.0   59.8 : 0      0.361
  Ascites                                                                                                                          
  Absence : Presence         56.9 : 47.2                         12.5 : 0                    \<0.001   82.6 : 33.3   55.9 : 33.3   0.095
  Prothrombin time (s)                                                                                                             
  \<14 : \>14                57.4 : 62.3                         52.1 : 51.0                 0.954     79.7 : 85.9   53.3 : 62.2   0.541
  Tumor number                                                                                                                     
  Solitary : Multiple        60.4 : 57.8                         51.2 : 46.2                 0.356     82.1 : 79.1   56.3 : 54.5   0.723
  Tumor size (cm)                                                                                                                  
  ≤5 : \>5                   68.4 : 52.2                         68.4 : 40.4                 0.012     86.5 : 73.0   63.5 : 49.3   0.088
  Location                                                                                                                         
  Central : Peripheral       56.6 : 61.6                         49.0 : 54.8                 0.515     86.9 : 77.3   55.3 : 53.7   0.303
  PVTT                                                                                                                             
  Absence : Presence         61.7 : 12.5                         55.2 : 0                    \<0.001   83.6 : 46.8   60.9 : 0      \<0.001
  Blood loss (ml) ^a^                                                                                                              
  ≤200 : \>200               59.1 : 57.7                         50.9 : 54.4                 0.890     83.1 : 71.5   55.3 : 57.8   0.446
  Blood transfusion                                                                                                                
  No : yes                   61.5 : 22.0                         53.8 : 0                    0.018     83.6 : 50.8   57.4 : 0      0.014
  Surgical margin (cm)                                                                                                             
  \<2 : ≥2                   51.8 : 61.8                         37.5 : 55.6                 0.129     71.4 : 85.3   53.5 : 57.4   0.143
  Resection approach                                                                                                               
  CC group : Habib4x group   52.3 : 65.6                         41.2 : 59.5                 0.033     72.8 : 86.5   44.2 : 61.8   0.030
  Pathological stage                                                                                                               
  I-II : III-IV              59.9 : 56.9                         53.5 : 49.0                 0.582     80.4 : 82.8   48.8 : 66.4   0.282

a Patients were divided according to the median value.

Abrreviations: CC, clamp-crush, HBsAg, hepatitis B virus surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; AFP, alpha-fetoprotein; PVTT, portal vein tumor thrombi.

###### Cox's regression analysis in matching patients

  Variables                         Recurrence-free survival   Overall survival                         
  --------------------------------- -------------------------- ------------------ --------------------- ---------
  Albumin (≤35:\>35 g/L)            \-                         \-                 2.857 (1.372-5.952)   0.005
  Ascites (Absence: Presence)       \-                         \-                 0.206 (0.047-0.900)   0.036
  Resection approach (Habib : CC)   0.488 (0.287-0.829)        0.008              0.449 (0.234-0.860)   0.016
  Tumor size (≤5 : \> 5 cm)         0.472 (0.268-0.831)        0.009              \-                    \-
  PVTT (absence : presence)         0.180 (0.083-0.392)        \<0.001            0.186 (0.079-0.439)   \<0.001

Abbreviation: HR, hazard rate; CI, confidence interval; CC, clamp-crush; PVTT, portal vein tumor thrombosis.

![Kaplan-Meier analyses of recurrence-free survival **A**. and overall survival **B**. of patients with HCC after matching.](oncotarget-08-4218-g003){#F3}

PVTT (hazard ratio \[HR\], 0.180; 95% confidence interval \[CI\] 0.083-0.392; *P* \< 0.001), tumor size (HR, 0.472; 95% CI: 0.268-0.831; *P* = 0.009), and resection method (HR, 0.488; 95% CI: 0.287-0.829; *P* = 0.008) were independent predictive factors of RFS, after adjusting for propensity score. PVTT (HR, 0.186; 95% CI: 0.079-0.439; *P* \< 0.001), albumin (HR, 2.857; 95% CI: 1.372-5.952; *P* = 0.005), resection method (HR, 0.449; 95% CI: 0.234-0.860; *P* = 0.016), and ascites (HR, 0.206; 95% CI: 0.047-0.900; *P* = 0.036) were independent prognostic factors for OS, after adjusting for propensity score.

In addition, resections of central tumors \[[@R11]\] and large tumors \[[@R12]\] were always associated with more blood loss and poor survival. Thus, we further stratified patients according to tumor location and tumor size. Central tumors were defined as previous: tumor located central segments (Couinaud's segments I, IV, V and VIII) and with a distance of ≥ 2 cm from the liver capsule. \[[@R11]\] For the 42 patients with central and large tumors (tumor size more than 5 cm), the Habib group had better RFS and OS (*P* = 0.035 and *P* = 0.038, respectively, Figures [4A and 4B](#F4){ref-type="fig"}). While, for the 92 patients with peripheral and small tumors (tumor size no more than 5 cm), two groups had similar RFS and OS (*P* = 0.117 and *P* = 0.126, respectively, Figure [4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

![After matching, Kaplan-Meier analyses of recurrence-free survival **A**. and overall survival **B**. of 42 patients with central and large HCCs. Kaplan-Meier analyses of recurrence-free survival C. and overall survival D. of 92 patients with peripheral or small HCCs.](oncotarget-08-4218-g004){#F4}

DISCUSSION {#s3}
==========

Although the safety and survival of patients who undergo ablation-assisted resections has been evaluated, \[[@R8], [@R13]\] there is still lack of results regarding the oncological outcome of Habib^TM^ 4X-assisted resections. As the best of our knowledge, this is the first study to investigate the long term oncological outcome due to the technique of resection. In the current study, patients in the Habib group had similar survival rates as those in the CC group before matching. After one-to-one PSM analysis, the Habib group was significantly associated with less blood loss, lower rates of blood transfusion, and shorter operation times, compared with the CC group. The Habib group had better RFS and OS compared to the CC group. In addition, patients with central or large tumors are better candidate for Habib^TM^ 4X-assisted resections, compared to the clamp-crush resection. This study supports the Habib^TM^ 4X providing safer resections and favorable survival for HCC patients.

During the past decade, there has been a significant increase in the number of liver resections. \[[@R14], [@R15]\] Still, resection comes with significant risks and the high frequency of complications. \[[@R16]\] In our study, the rates of severe complications before and after matching were 4.9% and 3.0%, respectively, for the Habib group, which were both relatively lower than patients in the CC group and previous studies. \[[@R17], [@R18]\] This indicates that Habib^TM^ 4X-assisted resection is a safe.

CC is recognized as a standard method of liver parenchymal transection over the past decades. However, CC often lead to excessive blood loss and more blood transfusions, which further influenced the safety and survival. \[[@R19]\] The Habib^TM^ 4X releases energy and produces a plane of coagulative necrosis along the intended line of parenchymal transection. \[[@R20]\] As this process reduce the risk of bleeding of hepatic parachymal, it thus ensured rapid hepatic parachymal division and shorted operation times. This may benefit cirrhotic patients. The rate of required blood transfusions was 12.3% (10/81), which was much lower than that for most previous studies. \[[@R21], [@R22]\]

Our data revealed that Habib^TM^ 4X-assisted resection provided better survival than the traditional clamp-crush method. One of the potential reasons is the coagulative necrosis zone formed by the Habib^TM^ 4X. This ablation zone was a tumor cell-free zone, which could kill potentially metastatic cells and decrease the risk of local recurrence. A clinical trial showed that narrow surgical margins increased intrahepatic recurrence \[[@R23]\]. Furthermore, a coagulative necrosis zone was made before the hepatic resection could reduce the risk of tumor cell intravasation and dissemination into the circulation. In addition, recently studies showed that after thermal ablation-mediated necrosis, tissue debris remains in the treated area, which may help active tumor-specific T cell response and increase the likelihood of tumor control. \[[@R24]--[@R26]\]

Studies from the team of Curro and Habib opened an eye for liver surgeon to recognize the Habib^TM^ 4X device, \[[@R27], [@R28]\] while there are still many problems need to be discussed, including long term oncological outcome. \[[@R29]\] An Italian study showed that ablation-assisted resection provides a clean surgical field, but it was associated with a higher rate of complications than clamp-crushing. \[[@R9]\] Recently, another study showed that ablation-assisted resection resulted in lower blood loss and fewer complications. \[[@R10]\] These two studies have controversial outcomes, and a meta-analysis was also unable to reach convincing outcomes. \[[@R30]\] While both of these studies had small sample sizes, lacked oncologic outcomes, and were based on monopolar ablation. \[[@R9], [@R10]\] We surmised that the HabibTM 4X, a bipolar ablation device, produce a better coagulative necrosis zone than with monopolar ablation. \[[@R31]\]

It is interesting to note that the Habib^TM^ 4X may provide favorable survival rates for central and large tumors. Resection for central and large tumors are always associated more blood loss and longer operation time. The advantage of Habib^TM^ 4X-assisted resection is more obviously for central and large tumors. While, the benefits of Habib^TM^ 4X over clamp-crush was unclear for peripheral or small tumors Thus, patients with central and large tumors were good candidate for Habib^TM^ 4X-assisted resection.

This study had limitations. Thermal damage from ablation may injure the neighboring vessels. Thus, the Habib^TM^4X requires skilled surgical techniques. Use of ultrasound guidance greatly decreases the risk of injury to large vessels. The Habib^TM^ 4X device should be operated by experienced surgeons. In our study, all resections were performed by Haiying Liu, who has performed at least 80 hepatic resection per year. Furthermore, with increased availability and practice of laparoscopy, laparoscopic HabibTM 4X procedures could greatly control blood loss. \[[@R20], [@R32]\] We have performed several hepatic resections with laparoscopic Habib^TM^ 4X. A large sample size study could provide more specific information on laproscopic Habib^TM^ 4X in the near future. In addition, a comparative study of Habib^TM^ 4X with other surgical tools, such as bipolar scissors and LigaSure diathermy, may broaden our understanding of Habib^TM^ 4X and increase hepatic resection device options. Finally, it should be noted that this is a retrospective and single-institution study. A prospective, multi-center study is needed to validate our findings.

CONCLUSIONS {#s4}
===========

In conclusion, Habib^TM^ 4X-assisted hepatic resection provides safety and survival benefits for patients with HCC who undergo hepatic resections, particularly for those with central and large tumors.

MATERIALS AND METHODS {#s5}
=====================

Study population {#s5_1}
----------------

Between January 2009 and December 2013, 183 patients underwent hepatic resections at Guangzhou Medical University Cancer Center. This retrospective study was approved by the Institutional Review Board at Guangzhou Medical University Cancer Center. All the patients were diagnosed with HCC. None had undergone liver transplantation, ablation, trans-arterial chemoembolization (TACE), or radiotherapy before resection.

Operative techniques {#s5_2}
--------------------

Patients underwent liver resections with general anesthesia. Intraoperative bimanual liver palpation and ultrasonography were then performed to confirm tumor and major vessel locations. If a resection plane was close to a secondary major vessel, resection was performed using the clamp-crush technique (CC group), which divides and seals the hepatic duct. If tumors were distal ( ≥ 1 cm) to the secondary major or major vessels, the Habib^TM^ 4X device was used to develop a coagulation plane and create a resection line with an argon diathermy 1-2 cm from the edge of the tumor (Habib group). For each application, 100 W were delivered, and the procedure took 5-15 s. According to the thickness and vascular distribution of the liver tissue, we repeated the above steps until a fully ablated zone of desiccation was created. The number of ablations required to obtain a zone of necrosis depended on the depth of the liver parenchyma to be resected. This zone of desiccation was related to the size of the cut resection margin surface.

Once ablation was completed, a scalpel was used to divide the parenchyma between the pair of needles. Following that, we ligated the large blood vessels and bile ducts with diameters larger than 7 mm, leaving only the coagulated liver parenchyma behind. These processes were repeated until the entire tumor was removed.

Follow-up {#s5_3}
---------

In this study, the Clavien-Dindo classification was used to accurately and objectively grade the severity of postoperative complications. \[[@R33], [@R34]\] Patients underwent contrast-enhanced CT or magnetic resonance imaging (MRI) of the abdomen and chest x-ray every 3 months for the first two years after resection and every 5-6 months subsequently for follow-up. Serum alpha-fetoprotein (AFP) levels and liver function were tested simultaneously. Recurrence diagnoses were made based on imaging alone if the tumor displayed typical enhancement characteristics. Extrahepatic tumors or those with atypical imaging characteristics were biopsied to confirm HCC. The data in this study were censored on February 1, 2016. Whenever possible, salvage treatment was administered to patients with recurrence or metastases. Repeat resections and ablations were the primary treatment choices for patients with solitary lesions or up to 3 lesions in total. Other non-radical treatments included transarterial chemoembolization (TACE).

Statistical analysis {#s5_4}
--------------------

Statistical analyses were performed using SPSS 20.0 (IBM, New York, NY, USA) and R version 2.12.1. OS was defined as the time from the date of resection to the date of death or the last follow-up. RFS was defined as the time from the date of resection to the time of recurrence, metastasis, or the last follow-up. RFS and OS rates were generated using the Kaplan-Meier method with log rank analyses. The Cox regression model was built using a stepwise variable selection.

PSM analysis was performed as described in our previous study \[[@R35]\]. Age, sex, tumor size, tumor number, tumor location, portal vein tumor thrombosis (PVTT), levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), albumin, total bilirubin, and ascites were the variables analyzed. Subsequently, 1:1 matching between the CC group and the Habib group was performed using the nearest neighbor matching. Once patients were matched, conditional logistic regression was used to compare survival. All *P* value calculations were 2-sided, and *P* \< 0.05 was considered statistically significant.

**CONFLICTS OF INTEREST**

None.

**FUNDING**

This work was supported by grants from the Guangzhou Science and Technology Plan Projects (Health Medical Collaborative Innovation Program of Guangzhou) (grant No. 201400000001-4), Natural Science Foundation of Guangdong (S2013010011766) and Guangzhou Medical University (2014C48).
